ID: ALA4211292

Max Phase: Preclinical

Molecular Formula: C23H18ClN3O4

Molecular Weight: 435.87

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)c1ccc(CN2C(=O)c3ccc(Cl)cc3NC(=O)[C@H]2Cc2ccccn2)cc1

Standard InChI:  InChI=1S/C23H18ClN3O4/c24-16-8-9-18-19(11-16)26-21(28)20(12-17-3-1-2-10-25-17)27(22(18)29)13-14-4-6-15(7-5-14)23(30)31/h1-11,20H,12-13H2,(H,26,28)(H,30,31)/t20-/m1/s1

Standard InChI Key:  JSFGGWBJZGWYEV-HXUWFJFHSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 435.87

Molecular Weight (Monoisotopic): 435.0986

AlogP: 3.64

#Rotatable Bonds: 5

Polar Surface Area: 99.60

Molecular Species: ACID

HBA: 4

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.94

CX Basic pKa: 4.65

CX LogP: 3.05

CX LogD: 0.78

Aromatic Rings: 3

Heavy Atoms: 31

QED Weighted: 0.64

Np Likeness Score: -0.89

References

1. Letourneau JJ, Stroke IL, Hilbert DW, Sturzenbecker LJ, Marinelli BA, Quintero JG, Sabalski J, Ma L, Diller DJ, Stein PD, Webb ML..  (2018)  Identification and initial optimization of inhibitors of Clostridium difficile (C. difficile) toxin B (TcdB).,  28  (4): [PMID:29331267] [10.1016/j.bmcl.2018.01.005]

2. Letourneau JJ, Stroke IL, Hilbert DW, Cole AG, Sturzenbecker LJ, Marinelli BA, Quintero JG, Sabalski J, Li Y, Ma L, Pechik I, Stein PD, Webb ML..  (2018)  Synthesis and SAR studies of novel benzodiazepinedione-based inhibitors of Clostridium difficile (C. difficile) toxin B (TcdB).,  28  (23-24): [PMID:30392779] [10.1016/j.bmcl.2018.10.047]

Source

Source(1):

• Scientific Literature